Trending: Steve Carell as Jeff Bezos on ‘Saturday Night Live’ trolls Trump just days after Amazon picks HQ2 sites

(Bigstock Photo)

There’s a new biotechnology spin-out from the University of Washington, and the company is already raising cash to get its technology off the ground.

Split Biosciences, which also goes by Split Bio, just raised a $1.2 million seed round. In an email to GeekWire, the company declined to identify the investors in the round, but did share details of its technology.

Split Bio co-founder Charlie Roco. (Photo via LinkedIn)

Split is developing a new method of sequencing cells’ RNA, the messenger molecules that communicate genetic instructions to proteins.

“In recent years, single-cell RNA-sequencing (scRNA-seq) has seen explosive growth both within academia and pharmaceutical companies. However, despite the widespread adoption of scRNA-seq in basic research and discovery, high costs and low throughput have limited its uses for many applications,” Charlie Roco, Split’s co-founder, said in the email.

To combat this, Split has created a faster sequencing process called SPLiT-seq. It was developed in the lab of synthetic biology professor Georg Seelig by Roco and Alex Rosenberg, two researchers at the lab. All three are co-founders of Split Bio.

Split Bio Co-founder Alex Rosenberg. (Photo via LinkedIn)

Traditionally, single-cell sequencing requires that all cells in a given sample — a biopsy of a tumor, for example — be physically separated before their DNA or RNA is sequenced. SPLiT-seq sidesteps that problem with new technology.

“SPLiT-seq leverages a combinatorial barcoding scheme to perform single-cell labeling of molecules without the need for cell isolation,” Roco said. “This ultimately enables researchers to scale up in both samples and cell numbers.”

Like what you're reading? Subscribe to GeekWire's free newsletters to catch every headline

Comments

Job Listings on GeekWork

Find more jobs on GeekWork. Employers, post a job here.